These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19195118)

  • 1. [Topics of prostate cancer].
    Tomida K
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):43-6. PubMed ID: 19195118
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy.
    Block M; Trump D; Rose DP; Cummings KB; Hogan TF
    Cancer Treat Rep; 1984 May; 68(5):719-22. PubMed ID: 6722829
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of prostatic cancer (Drug Administration, Sweden)].
    Lakartidningen; 1993 May; 90(18):1766, 1769-73. PubMed ID: 8492635
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program].
    Fourcade RO; Richaud P; Coloby P; Malavaud B;
    Prog Urol; 2007 Jun; 17(4 Suppl 1):891-910. PubMed ID: 17650746
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!
    Raghavan D
    Br J Cancer; 2004 Sep; 91(6):1003-4. PubMed ID: 15475939
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?
    Sartor O
    J Clin Oncol; 2009 May; 27(15):2417-8. PubMed ID: 19364953
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain metastases in hormone refractory prostate cancer: a changing natural history?
    Roberts-Thomson R; Rosenthal MA; Gonzales M; Drummond K
    Intern Med J; 2009 Mar; 39(3):205-6. PubMed ID: 19383072
    [No Abstract]   [Full Text] [Related]  

  • 8. Bicalutamide-induced gynaecomastia: do we have the answer?
    Di Lorenzo G; Autorino R
    Eur Urol; 2007 Jul; 52(1):5-8. PubMed ID: 17258386
    [No Abstract]   [Full Text] [Related]  

  • 9. [What is the role of neoadjuvant therapy in prostate cancer?].
    Witjes WP; Horenblas S; Oosterhof GO; Schaafsma HE; Debruyne FM
    Minerva Urol Nefrol; 1995 Dec; 47(4):209-14. PubMed ID: 8711594
    [No Abstract]   [Full Text] [Related]  

  • 10. To what degree is chemotherapy useful in the treatment of prostatic cancer.
    Murphy GP
    Prog Clin Biol Res; 1987; 243B():247-53. PubMed ID: 3309984
    [No Abstract]   [Full Text] [Related]  

  • 11. Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico.
    Slovin SF
    IDrugs; 2005 Sep; 8(9):710-2. PubMed ID: 16118688
    [No Abstract]   [Full Text] [Related]  

  • 12. [Apropos of hormone-independent cancer of the prostate].
    Chauvin HF
    J Urol Nephrol (Paris); 1967 Mar; 73(3):334-6. PubMed ID: 6054950
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of metastron in the treatment of prostate cancer].
    Garcia-Giralt E; Omodei Zorini C
    Clin Ter; 1997; 148(1-2):1-5. PubMed ID: 9377832
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy for advanced prostate cancer: 25 years later.
    Logothetis CJ; Millikan R
    J Clin Oncol; 2008 May; 26(15):2423-4. PubMed ID: 18487561
    [No Abstract]   [Full Text] [Related]  

  • 15. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
    Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
    Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary endobronchial non-Hodgkin lymphoma in an 80-year-old patient with prostate cancer.
    Hardavella G; Thalassinos N; Anastasiou N
    Interact Cardiovasc Thorac Surg; 2009 Oct; 9(4):739-40. PubMed ID: 19589791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 18. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis.
    Heidenreich A
    Eur Urol; 2008 Oct; 54(4):726-7. PubMed ID: 18524468
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prognosis and predictive factors in prostate cancer].
    Albiges-Sauvin L; Lévy A; Massard C; Fizazi K
    Bull Cancer; 2009 Apr; 96(4):439-49. PubMed ID: 19357018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.